

# Abstract 3033: Prognostic value of plasma hPG<sub>80</sub>, alone or in combination with AFP in patients with hepatocellular carcinoma

Authors: Eric Assenat<sup>1</sup>, Marie Dupuy<sup>1</sup>, Sarah Iltache<sup>1</sup>, Bérengère Vire<sup>2</sup>, Julien Soulé<sup>2</sup>, Pierre Liaud<sup>2</sup>, Thierry Cousin<sup>3</sup>, Younes Mahi<sup>3</sup>, Dominique Joubert<sup>3</sup> and Alexandre Prieur<sup>3</sup>

<sup>1</sup>Department of Medical Oncology, CNRS UMR 5535 St-Elloi University Hospital Montpellier School of Medicine, 80, Avenue Augustin Fliche 34295 Montpellier, France; <sup>2</sup>Eurobiodev, 2040 avenue du Père Soulas, 34000 Montpellier, France; <sup>3</sup>ECS-Progastrin, Chemin de la Meunière 12, 1008 Prilly, Switzerland.







## Background:

- Alpha-fetoprotein (AFP) is the most widely used biomarker for hepatocellular carcinoma (HCC) prognosis since it is mostly expressed in the advanced stages of the disease.
- Consequently, beyond AFP we need new biomarker in establishing a prognosis for patients specially with a tumor in the early stages of the disease.
- hPG<sub>80</sub> (circulating progastrin), a new drug target for cancer treatment which plays a pivotal role in tumorigenesis, is present in the blood of multiple types of cancers at early stages including HCC.

## Methods:

- The ELISA DxPG80.lab kit (ECS-Progastrin, Switzerland) was used to measure hPG80 levels in all plasma EDTA samples according to the manufacturer's instruction
- The blood-based biomarker AFP (alpha foeto-protein) concentrations were centrally measured using Cobas E411.

Clinical and pathological characteristics for HCC patients		N (%)
		n = 168
Age, years	Median (range)	67 (27-85)
Gender	Male	149 (88.7%)
	Female	19 (11.3%)
Laboratory values		
hPG <sub>80</sub>	Median (IQR), pM	7.64 (2.53-28.28)
	Mean (SE), pM	25.52 (4.16)
AFP	Median (IQR), ng/mL	40.20 (5.55-712.50)
	Mean (SE), ng/mL	5066 (2340)



## Conclusions:

- Our findings show that hPG<sub>80</sub> could serve as a new prognostic biomarker in HCC.
- Used in combination with AFP, it improves the stratification of the patients in good and worst prognosis, especially for those patients with negative AFP and early-stage HCC.